Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE)--Oct 12, 2019--
NEW YORK--(BUSINESS WIRE)--Oct 12, 2019--